Prostate Cancer International is a
non-profit for 2012 as rated by Great NonProfits
Over the past 24 hours there’s been media noise generated by a company called Mirna Therapeutics based on a company media release and a Letter to the Editor in Nature Medicine about how a specific piece of microRNA (miR-34) is down-regulated in prostate cancer stem cells and that this down-regulation is essential for viability of cancer stem cells. … READ MORE …
Filed under: Drugs in development | Tagged: microRNA, miR-34 | Leave a Comment »
We still have little to no idea why one man gets aggressive prostate cancer, another gets indolent prostate cancer, and a third is at no risk for prostate cancer at all. … READ MORE …
Filed under: Drugs in development, Management, Prevention | Tagged: microRNA, risk, systems biology | Leave a Comment »
A new paper by Wang et al. in a recent issue of Cancer Research has proposed details of a specific connection between control over the growth and division of prostate cancer cells and clinical occurrence of the more aggressive forms of prostate cancer. … READ MORE …
Filed under: Management, Risk | Tagged: aggressive, cell, indolent, messenger RNA, microRNA, regulation | 3 Comments »
In addition to the reports on the early stages of the RALP learning curve and quality of life outcomes post-brachtherapy, there are a large number of additional reports in today’s news: … READ MORE …
Filed under: Diagnosis, Drugs in development, Management, Treatment | Tagged: Alpharadin, arginine deiminase, bladder neck stent, fiducial marker, high-dose external beam radiation, microRNA, pelvic lymph node dissection, PNLD, radium-223, vaccine therapy | Leave a Comment »
Search for new and
ongoing trials on the
CTAG PCa web site